SPOTLIGHT: FDA accelerates Provenge timeline

More news in the ongoing Dendreon/Provenge saga. The FDA has agreed to amend Dendreon's Special Protocol Assessment (SPA) for a Phase III trial of Provenge, the company's prostate cancer treatment candidate. The amended SPA accelerates the expected timing of the trial results by about one year. Release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.